

- Practice guidelines, 3, 28  
 PRAD 1, 2471f  
 Prader-Willi syndrome  
   clinical features of, 415e-4, 415e-5t, 439, 2256, 2364  
   genetic considerations in  
     imprinting, 83e-7, 415e-5t, 439, 444e-2, 2256, 2364  
     uniparental disomy, 439  
     X-inactivation, 439  
 Pragmatics, 179  
 Pralatrexate, 103e-11t  
 2-Pralidoxime chloride (2-PAM Cl), 262e-5t, 262e-6, 262e-6f, 473e-10t  
 Pramipexole  
   adverse effects of, 2615  
   for PD, 2615, 2616t  
   for restless legs syndrome, 188t, 192, 2625  
 Pramlintide, 2412–2413, 2414t  
 Prasugrel  
   action of, 747  
   adverse effects of, 404, 747  
   for cardiac catheterization pretreatment, 1461  
   vs. clopidogrel, 747  
   contraindications to, 1596  
   dosage of, 747  
   genetic variation in response to, 277t, 743t  
   for ischemic heart disease, 1590  
   management before endoscopic procedures, 1889t  
   for myocardial infarction, 1596, 1598, 1598t, 1606  
   in PCI, 296e-1, 296e-2, 1596  
   resistance to, 747  
 Prausnitz-Küstner reaction, 2116  
 Pravastatin, 2199, 2218t, 2448t  
 Praziquantel  
   action of, 246e-12  
   adverse effects of, 246e-6t, 246e-12  
   for biliary flukes, 1428t  
   for cysticercosis, 1432  
   for diphyllorhynchiasis, 1434  
   for echinococcosis, 1434  
   for *H. nana* infections, 1434  
   indications for, 246e-6t  
   for intestinal flukes, 1428t  
   for lung flukes, 1428t  
   for neurocysticercosis, 903  
   pharmacology of, 246e-12  
   in pregnancy and lactation, 246e-6t  
   for schistosomiasis, 246e-12, 1428, 1428t  
   for *T. asiatica* infection, 1430  
   for *T. saginata* infection, 1430  
   for *T. solium* infection, 1432  
 Prazosin  
   adverse effects of, 2640t  
   for ergot alkaloid overdose/poisoning, 473e-8t  
   for hypertension, 1624t  
   for PTSD, 471e-5, 2712  
   for Raynaud's phenomenon, 1649, 2164  
 Prealbumin. *See* Transthyretin (TTR)  
 Pre-Bötzinger complex, 1720  
 Precipitation, patterns of, 151e-3–4  
 Precocious puberty  
   female  
     definition of, 2380  
     diagnosis of, 2380t  
     differential diagnosis of, 2380t  
     etiology of, 2380  
     ovarian germ cell tumors and, 594  
   male, 2361  
   approach to the patient, 2362  
   breast enlargement in, 2362  
   in congenital adrenal hyperplasia, 2362  
   definition of, 2361  
   etiology of, 2361t  
   familial male-limited, 2362  
   genetic considerations in, 437, 2252  
   gonadotropin-dependent, 2361  
   gonadotropin-independent, 2361  
   in McCune-Albright syndrome, 2362. *See also* McCune-Albright syndrome  
   treatment of, 2362  
 Preconceptual diagnosis, 444  
 Preconditioning, kidney, 333e-3–4, 333e-4t  
 Precordial thump, 1768  
 Precursor B-cell lymphoblastic leukemia/  
   lymphoma, 91e-4, 701  
 Precursor cells, 454  
 Precursor T-cell lymphoblastic leukemia/  
   lymphoma, 702t, 707  
 Prediction models, 23–24, 24t  
 Predictive value of test, 22  
 Predisposition testing, 448  
 Prednisolone  
   for alcoholic liver disease, 2053, 2054f  
   for asthma, 1677  
   for chorea, 2153  
   for COPD exacerbation, 1707  
   for optic neuritis, 202  
   for rheumatic fever, 2153  
 Prednisone  
   for ACTH deficiency, 2260  
   for acute idiopathic pericarditis, 1573  
   for adult hypopituitarism, 2259t  
   adverse effects of, 462e-19, 2129, 2145, 2200–2201. *See also* Glucocorticoid(s), adverse effects of  
   for alcoholic liver disease, 2053, 2054f  
   for allergic rhinitis, 2124  
   for asthma, 1677  
   for autoimmune hemolytic anemia, 658  
   for autoimmune hepatitis, 2051–2052  
   for autoimmune pancreatitis, 2099  
   for Behçet's syndrome, 2194  
   for Bell's palsy, 2648  
   for bullous pemphigoid, 372  
   for CAH, 334  
   for cancer treatment-induced pneumonitis, 622  
   for chorea, 2153  
   for chronic inflammatory demyelinating polyneuropathy, 2699  
   for cluster headache prevention, 2595, 2595t  
   for contact dermatitis, 345  
   for drug-induced hypersensitivity syndrome, 382  
   for Duchenne's muscular dystrophy, 462e-8  
   for eosinophilic fasciitis, 376  
   for gastric lymphoma, 536  
   for giant cell arteritis, 2189  
   for gout, 2234  
   for Graves' ophthalmopathy, 207  
   for hypercalcemia, 314  
   for hypercalcemia of malignancy, 610  
   for hyper eosinophilic syndrome, 135e-8  
   for hypersensitivity pneumonitis, 1683  
   for IBD, 1960  
   for idiopathic cutaneous vasculitis, 2192  
   for idiopathic pulmonary fibrosis, 1712  
   for IgA vasculitis, 2190  
   for IgG4-related disease, 391e-3  
   for immune thrombocytopenic purpura, 728  
   for immunosuppression, 1828  
   for inflammatory myopathies, 2200  
   for interstitial lung diseases, 1711  
   for lepra reactions, 1127  
   for loiasis, 1422  
   for minimal change disease, 1842  
   for MS, 2667  
   for mucous membrane pemphigoid, 374  
   for multiple myeloma, 716–717  
   for myasthenia gravis, 2705  
   for neurocysticercosis, 903  
   for PCP, 1361t  
   for pemphigoid gestationis, 373  
   for pemphigus vulgaris, 371  
   for polymyalgia rheumatica, 2189  
   for postherpetic neuralgia, 1186  
   for Q fever, 1162  
   for relapsing polychondritis, 2204  
   for rheumatic fever, 2153  
   for rheumatoid arthritis, 2145  
   for sarcoidosis, 2211, 2212t  
   for serum sickness, 2737  
   for sinusitis with hyposmia, 216  
   for SJS and TEN, 383  
   for SLE, 2132  
   for subacute thyroiditis, 2299  
   for thymoma, 123e-2  
   for tonsillar hypertrophy, 1189  
   for trichinellosis, 1411t  
   for vasculitic neuropathy, 2700  
   for VIPoma, 571  
 Preeclampsia, 45  
   clinical features of, 46  
   definition of, 45  
   diagnosis of, 46  
   in gestational trophoblastic disease, 597  
   KIRs with, 372e-15t  
   pathophysiology of, 46  
   risk factors for, 45  
   treatment of, 46, 1626t  
 Prefrontal network, 183  
 Pregabalin  
   adverse effects of, 2682t  
   for anxiety disorders, 2711  
   for fibromyalgia, 2240, 2240t  
   for hot flashes, 623  
   for neuropathy, 2427, 2682t  
   for pain, 61, 91t, 94, 2101, 2672  
   for status epilepticus, 2558f  
 Pregnancy, 45  
   abdominal swelling in, 285  
   acute fatty liver of, 49  
   age of first full-term, breast cancer risk and, 524  
   alcohol use in, 2725  
   antibacterial therapy in, 936, 937t  
   antiparasitic agents in, 246e-1–7t  
   antiphospholipid syndrome in, 2135t, 2136  
   aortic regurgitation in, 46–47  
   aortic stenosis in, 46–47  
   aplastic anemia in, 664  
   asthma in, 1680  
   asymptomatic bacteriuria in, 49–50, 862  
   AVP assays in, 304  
   bacterial infections in, 49–50  
   breast cancer in, 124e-1t, 124e-3–4, 124e-3t  
   breast mass in, 124e-3, 525–526  
   *C. trachomatis* infection in, 1169, 1171  
   cancer chemotherapy during, 103e-26, 124e-1, 124e-2  
   cardiomyopathy in, 47, 1562  
   cervical cancer during, 124e-1t, 124e-2–3  
   cholestasis in, 49, 284, 2029, 2078  
   chronic kidney disease in, 46, 1819  
   CML treatment during, 694  
   CMV infection in, 50, 1191  
   cobalamin deficiency in, 642  
   congenital heart disease and, 47, 1519, 1522, 1528  
   depression in, 6e-5  
   diabetes insipidus in, 303  
   diabetes mellitus in, 6e-3–4, 47–48, 2400, 2422  
   DIC in, 737  
   DVT in, 47  
   ectopic, 338  
   edema in, 253  
   epilepsy and, 49, 2559  
   erythema infectiosum in, 127  
   fatigue in, 152  
   filovirus infections in, 1328  
   folate deficiency in, 642–643, 646  
   folate requirement in, 47, 265e-12, 643, 646, 648  
   gallbladder disease in, 49, 2078  
   gastrointestinal disease in, 49  
   GBS infection in, 970  
   genital herpes in, 50  
   gonococcal infections in, 1006, 1008  
   Graves' disease in, 2297  
   HBV infection in, 49  
   headache in, 49  
   heart disease in, 46–47  
   heart murmurs in, 51e-6  
   HELLP syndrome in, 46, 49, 1865, 2019  
   hematologic disease in, 49  
   hemoglobin/hematocrit in, 394t  
   hemoglobinopathy in, 49